Trial Profile
A phase 2 study of KRd(carfilzomib, lenalidomide, dexamethasone) consolidation for newly diagnosed multiple myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2022
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms OCHA-KRd
- 27 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 19 Dec 2019 Planned number of patients changed from 22 to 21.
- 19 Dec 2019 Planned End Date changed from 21 May 2022 to 17 Dec 2024.